Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Other Non-Current Assets (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Other Non-Current Assets for 10 consecutive years, with $2000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets changed 0.0% to $2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $2000.0 for FY2025, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2000.0 at Rein Therapeutics, roughly flat from $2000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $2.3 million in Q2 2025, with the low at $2000.0 in Q3 2024.
  • Average Other Non-Current Assets over 5 years is $317050.0, with a median of $24500.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets skyrocketed 8672.0% in 2023, then crashed 99.91% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $25000.0 in 2021, then changed by 0.0% to $25000.0 in 2022, then surged by 8672.0% to $2.2 million in 2023, then plummeted by 99.91% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2000.0, $2000.0, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.